Prevalence, Incidence, and Factor Concentrate Usage Trends of Hemophiliacs in Taiwan

Tsu-Chiang Tu,1,2 Wen-Shyong Liou,3,4 Tsui-Yun Chou,5 Tsung-Kun Lin,2 Chuan-Fang Lee,2 Jye-Daa Chen,2 Thau-Ming Cham,1 and Mei-Ing Chung1

1School of Pharmacy, Kaohsiung Medical University, Kaohsiung; 2Department of Pharmacy Practice, Tri-Service General Hospital, Taipei; 3Department of Pharmacy, Taichung Veterans General Hospital, Taichung; 4College of Pharmacy, China Medical University, Taichung; 5The Hemophilia Care and Research Center, Tri-Service General Hospital, Taipei, Taiwan.

Received: November 22, 2011
Revised: March 1, 2012
Accepted: March 9, 2012
Corresponding author: Dr. Mei-Ing Chung, School of Pharmacy, Kaohsiung Medical University, No 100 Shi-Chuan 1st Road, Kaohsiung 807, Taiwan. Tel: 886-7-3121101 #2672, Fax: 886-7-3210683 E-mail: meinch@kmu.edu.tw

Purpose: Hemophilia A and B (HA, HB) are the most common X-linked inherited bleeding disorders. The introduction of factor concentrates has allowed for control of the lifelong chronic disease. However, no studies have been published regarding the epidemiology of hemophilia in Taiwan. Our aim was to determine the prevalence, incidence, and mortality rate, as well as trends in the use of factor concentrates, in individuals with hemophilia in Taiwan.

Materials and Methods: A retrospective study was conducted using the National Health Insurance Research Database between 1997 and 2007.

Results: We identified 988 males with hemophilia (HA : HB ratio=5.4 : 1). The mean prevalence per 100000 males was 6.7±0.1 for HA and 1.2±0.1 for HB. The estimated mean annual incidence per live male birth was 1 in 10752 for HA and 1 in 47619 for HB. Standardized mortality ratios for males with hemophilia (all severities) or severe hemophilia were 1.3- and 2.1-fold higher than that of the general male population, respectively. Mean factor VIII (FVIII) and factor IX (FIX) usage was 1.5003±0.4029 and 0.3126±0.0904 international units (IUs) per capita, respectively. Mean FVIII and FIX usage per patient with hemophilia (all severities) or severe hemophilia was 44027±11532 and 72341±17298, respectively, and 49407±13015 and 74369±18411 IUs per person with HA or HB, respectively.

Conclusion: Our data revealed epidemiologic and factor concentrate usage trends in males with hemophilia in Taiwan, highlighting a need for improvements in the mandatory National Health Insurance registry. A better-designed, patient-centered registry system would enable more detailed patient information collection and analysis, improving subsequent care.

Key Words: Hemophilia, prevalence, incidence, factor VIII, factor IX, Taiwan

INTRODUCTION

Hemophilia A (HA) and B (HB) are the most common X-linked inherited bleeding disorders, resulting from clotting factor VIII (FVIII) and factor IX (FIX) deficien-
Facing spiraling growth in medical costs, the payment system for the NHI changed from a fee-for-service to a global budget in 2002 in order to keep health-care costs under control without impeding the quality of care. To better manage medical expenditures and enhance the professional autonomy of medical providers, other payment methods have since been introduced, such as pay-for-performance, diagnosis-related groups, and a resource-based relative value scale system, in recent years.

Since implementing the NHI, the BNHI has cooperated with the National Health Research Institute, a non-profit research organization founded and sponsored by the Department of Health, to establish National Health Insurance Research Databases (NHIRDs). The national claim data first became available in 1997. A retrospective study was conducted using data from the NHIRDs for the period between January 1997 and December 2007.

**Epidemiologic study**

The study subjects were identified from the 1997-2007 Registries for Catastrophic Illness patient files, which included the following data: scrambled identifier, gender, diagnosis, date of birth, date of hospital application, disease severity, and date of death, etc. Each patient was identified by a single, unique code that was retained even if the patient left and later re-enrolled in the system, assuring that no patient was evaluated more than once in the study.

Prevalence (per 100000 males per year) was defined as the total number of identified male hemophiliacs in the general male population divided by the total number of the general male population in the relevant year. Incidence (per 100000 live male births per year) was defined as the number of males with hemophilia among general male new-borns divided by the total number of general male new-borns in the relevant year.

The crude mortality rate was expressed as the number of deaths among males with hemophilia in the cohort per 100000 person-years at risk. The age-standardized mortality rate (per 100000 males) was based on the World Health Organization (WHO) standardization weight factors.

Standardized mortality ratio (SMR) was computed to
compare the mortality rate to that of the entire Taiwan male population using the ratio of the observed-to-expected mortality. The number of expected deaths was calculated for the cohort by multiplying the number of person-years of follow-up for 5-year age categories (0-4, 5-9...80-84, 85-89, and >89 years) by the corresponding age-specific mortality rates in the general Taiwan male population and summing the results over the age groups. Age-specific mortality rates for the general Taiwan male population in 2002 were used to calculate the SMR for the study population followed between 1997 and 2007. The general male population statistics and mortality rate data were obtained from the Taiwan Ministry of Interior and Department of Health, respectively.12,13

**Factor usage trend study**

To analyze trends in factor concentrate usage, data were derived from the following original claim data: ambulatory care expenditures by visits (CD); inpatient expenditures by admissions (DD); details of ambulatory care orders (OO); details of inpatient orders (DO); and registry for drug prescriptions (DRUG). Insurance claims data consisted of the date of visits or hospitalization, patient demographics (scrambled identifier, gender, and date of birth), medical facility visited, ICD-9-CM diagnosis codes, procedure codes, special procedures, and details for prescription drug use. DRUGs detailed the drug code, drug name, content name, content unit, and dosage form.

FVIII or FIX usage (IUs per capita) was defined as the total number of IUs consumed divided by the total population for the relevant year. FVIII or FIX usage per patient [IUs per person with hemophilia A (PWHA) or person with hemophilia B (PWHB)] was defined as the total number of IUs consumed divided by the HA or HB subjects for the relevant year, which was similar to that reported by Stonebraker, et al.14

**Statistical analysis**

Descriptive statistics were reported as the mean and standard deviation to describe the distribution of data for prevalence, incidence, and factor usage. Regression analyses were performed on a yearly basis to determine the association of factor usage; the strength of the association was assessed by the correlation coefficient (R), and the slope of the regression line (S) over time was provided by a measure of annual trend. Ninety-five percent confidence intervals were calculated for mortality rate, based on Poisson’s distribution. All statistical analyses were conducted using STATA software version 11.0 (StataCorp LP, Lakeway, TX, USA).15

### RESULTS

**General population characteristics**

Fig. 1 is a flow chart of the enrollment of subjects included in this study. There were 988 patients with hemophilia, among which 833 patients were identified with HA and 155 patients with HB. Table 1 shows the characteristics of patients and comprises a total of 9951 person-years of observation. In this population, the ratio of HA : HB was 5.4 : 1. Hemophilia was characterized as severe in 574 patients (58.1%), moderate in 138 patients (14.0%), and mild in 276 (27.9%) individuals. Fifty-five patients died prior to the conclusion of this study in 2007, and 933 patients were still living. Of the surviving patients, 279 (29.9%) were 18 years of age or younger, while 654 (70.1%) were older than 18 years. For the surviving patients with HA, the mean age was 29.7±17.1 years, and that for surviving patients with HB was 27.2±17.7 years.

Consecutive data for the male hemophiliacs (newborns and deceased patients) are shown in Table 2. The number of 1997-2007 registration files for catastrophic illness patients
n=13285657

Exclude not deficiency of clotting factors diagnosis patients
n=13265011

1997-2007 registration files for deficiency of clotting factors
n=20646

Patient-centered unique identifier review exclude duplication
n=19245

Registration files for deficiency of clotting factor patients
n=1401

Exclude not factor VIII or factor IX disorder patients
n=360

Registration files for factor VIII or factor IX disorder patients
n=1041

Exclude factor VIII or factor IX disorder female patients
n=53

Registration files for factor VIII or factor IX disorder male patients
n=988

Registration files for Haemophilia B male patients n=155

Registration files for Haemophilia A male patients n=833

**Fig. 1. Flow chart for inclusion.**
annual prevalence (per 100000 males) was 6.7±0.1 for HA, 1.2±0.1 for HB, and 7.9±0.1 for HA+HB.

Fig. 2 shows the mean incidence of hemophilia (per 100000 live male births per year) at 5-year intervals (1978-1982, 1983-1987, 1988-1992, 1993-1997, 1998-2002, and 2003-2007) between 1978 and 2007. The mean incidence for the six consecutive periods ranged between 8.6 and 10.3 (9.3±0.7) for HA, 1.7 and 2.9 (2.1±0.5) for HB, and 10.4 and 12.6 (11.4±0.8) for HA+HB. The estimated average incidence of live male births per year was 1 in 10752 for HA, 1 in 47619 for HB, and 1 in 8772 for HA+HB.

The mortality rate per 100000 person-years and SMR

Table 1. General Characteristics According to Type of Hemophilia

|                  | HA         | HB         | Hemophiliacs (HA+HB) |
|------------------|------------|------------|----------------------|
| Patients         | 833        | 155        | 988                  |
| Person-years     | 8399       | 1552       | 9951                 |
| Patients severity (%) |           |            |                      |
| Severe           | 480 (57.6) | 94 (60.6)  | 574 (58.1)           |
| Moderate         | 110 (13.2) | 28 (18.1)  | 138 (14.0)           |
| Mild             | 243 (29.2) | 33 (21.3)  | 276 (27.9)           |
| Patient status, no. (%) |      |            |                      |
| Alive            | 784 (94.1) | 149 (96.1) | 933 (94.4)           |
| Deceased         | 49 (5.9)   | 6 (3.9)    | 55 (5.6)             |

Table 2. Consecutive Data of Male Hemophiliacs, Newborns, and Deceased Patients with Hemophilia during the Study Period

| Year | Patients |          |          |          |          |          |          |          |          |          |          |
|------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
|      | HA       | HB       | HA+HB    | HA       | HB       | HA+HB    | HA       | HB       | HA+HB    | HA       | HB       | HA+HB    |
| 1997 | 728      | 130      | 858      | 735      | 132      | 867      | 749      | 134      | 883      | 751      | 140      | 891      |
| 1998 | 735      | 132      | 867      | 749      | 134      | 883      | 751      | 140      | 891      | 751      | 140      | 891      |
| 1999 | 749      | 134      | 883      | 751      | 140      | 891      | 774      | 143      | 903      | 774      | 143      | 903      |
| 2000 | 762      | 140      | 903      | 774      | 143      | 903      | 774      | 145      | 907      | 774      | 145      | 907      |
| 2001 | 767      | 140      | 907      | 774      | 143      | 907      | 780      | 145      | 917      | 780      | 145      | 917      |
| 2002 | 774      | 140      | 917      | 780      | 143      | 917      | 785      | 145      | 925      | 785      | 145      | 925      |
| 2003 | 780      | 140      | 925      | 785      | 143      | 925      | 785      | 145      | 932      | 785      | 145      | 932      |
| 2004 | 785      | 140      | 932      | 785      | 143      | 932      | 785      | 145      | 933      | 785      | 145      | 933      |
| 2005 | 784      | 140      | 933      | 785      | 143      | 933      | 785      | 145      | 935      | 785      | 145      | 935      |
| 2006 | 784      | 140      | 935      | 785      | 143      | 935      | 785      | 145      | 935      | 785      | 145      | 935      |
| 2007 | 784      | 140      | 935      | 785      | 143      | 935      | 785      | 145      | 935      | 785      | 145      | 935      |

HA, hemophilia A; HB, hemophilia B.

Epidemiologic profile

The annual prevalence of HA (per 100000 males) increased from 6.5 in 1997 to 6.8 in 2007. The annual prevalence of HB (per 100000 males) increased from 1.2 in 1997 to 1.3 in 2007. The annual prevalence of HA+HB (per 100000 males) increased from 7.7 in 1997 to 8.1 in 2007. The mean annual prevalence (per 100000 males) was 6.7±0.1 for HA, 1.2±0.1 for HB, and 7.9±0.1 for HA+HB.

Fig. 2 shows the mean incidence of hemophilia (per 100000 live male births per year) at 5-year intervals (1978-1982, 1983-1987, 1988-1992, 1993-1997, 1998-2002, and 2003-2007) between 1978 and 2007. The mean incidence for the six consecutive periods ranged between 8.6 and 10.3 (9.3±0.7) for HA, 1.7 and 2.9 (2.1±0.5) for HB, and 10.4 and 12.6 (11.4±0.8) for HA+HB. The estimated average incidence of live male births per year was 1 in 10752 for HA, 1 in 47619 for HB, and 1 in 8772 for HA+HB.

The mortality rate per 100000 person-years and SMR
based on disease type of hemophilia are shown in Table 3. The overall crude mortality rate and age-standardized mortality rate for all individuals with hemophilia were 574.0 (95% CI, 528.0-622.9) and 693.3 (95% CI, 642.4-746.6), respectively. As expected, the crude mortality rate and age-standardized mortality rates were somewhat higher for patients with severe hemophilia. Among the general male population of Taiwan, the overall SMR was 1.4 for individuals with HA, and 1.3 for all individuals with hemophilia. For patients with severe hemophilia, the SMR was two times higher than that for the general male population.

**Factor usage**

Fig. 3 summarizes factor usage data inclusion. The time-series results for FVIII and FIX usage (IUs per capita) during the period of 1997-2007 are presented in Table 4. FVIII usage (IUs per capita) increased over time, from 0.9583 in 1997 to 2.2793 in 2007 (a 2.4-fold increase). Additionally, FVIII usage (IUs per capita) of plasma-derived concentrates showed an 82% reduction to 0.1686 in 2007 beginning in 1997. At the same time, FVIII recombinant concentrate use increased to 2.1104 in 2007, a 9.2-fold increase from 1999 to 2007. FIX usage (IUs per capita) increased over time (0.2306 in 1997 to 0.4644 in 2007; a 2-fold increase). Furthermore, FIX usage (IUs per capita) of plasma-derived concentrates decreased by 40% to 0.1374 in 2007. FIX recombinant concentrate use was 0.3270 in 2007 (a 5.2-fold increase from 2002 to 2007). The mean FVIII usage was 1.5003±0.4029 and showed an annual growth of

---

**Table 3. Crude, Standardized Mortality Rates (Per 100000 Males Per Year) and Rate Ratios during the 1997-2007 Period**

|                      | HA            | HB            | Hemophiliacs (HA+HB) |
|----------------------|---------------|---------------|----------------------|
| **Crude mortality rate (95% CI)** |               |               |                      |
| All severities       | 594.4 (547.2-643.7) | 505.3 (461.9-551.0) | 574.0 (528.0-622.9) |
| Severe               | 646.5 (597.1-697.8) | 631.3 (582.7-682.2) | 639.1 (590.4-690.5) |
| Moderate             | 594.5 (547.2-643.8) | 446.4 (405.6-489.4) | 520.1 (476.3-566.7) |
| Mild                 | 548.5 (504.0-596.9) | 137.7 (115.9-163.0) | 504.3 (460.9-550.0) |
| **Age-standardized mortality rate (95% CI)** |               |               |                      |
| All severities       | 684.4 (633.7-737.2) | 625.2 (577.0-676.0) | 693.3 (642.4-746.6) |
| Severe               | 738.9 (686.7-794.3) | 572.2 (526.1-620.8) | 719.0 (667.4-773.5) |
| Moderate             | 695.3 (644.3-748.6) | 377.5 (340.8-418.1) | 587.6 (541.4-637.5) |
| Mild                 | 443.1 (402.7-486.2) | 134.5 (113.2-159.8) | 521.3 (477.2-567.7) |
| **Standardized mortality ratio** |               |               |                      |
| All severities       | 1.4 (1.0-1.9)   | 1.0 (0.8-1.4)  | 1.3 (0.9-1.9)       |
| Severe               | 2.1 (1.7-2.7)   | 2.0 (1.6-2.6)  | 2.1 (1.7-2.7)       |
| Moderate             | 1.4 (1.0-1.9)   | 1.0 (0.8-1.4)  | 1.4 (1.0-1.9)       |
| Mild                 | 0.8 (0.5-1.1)   | 0.3 (0.1-0.6)  | 0.7 (0.4-1.0)       |

HA, hemophilia A; HB, hemophilia B; CI, confidence interval.
The mean FIX usage per patient for those with severe HB was 74369±18411, with an annual growth of 4923 IUs per PWHB. In those with moderate HB, FIX usage per patient (IUs per PWHB) showed a dramatic 5.1-fold increase, from 5996 in 1999 to 30741 in 2007. Notably, in those with mild HB, FIX usage per patient (IUs per PWHB) showed no difference between the years of 1997 and 2007, although usage did drop during this period.

DISCUSSION

This is the first study to report population-based data for hemophilia in Taiwan. The objectives of this study were to determine baseline epidemiologic profiles and factor concentrate usage trends for hemophiliacs in Taiwan.

Epidemiologic profile

The mean prevalence of HA (all severities) for our research

Table 4. Factor VIII and Factor IX Usage (IUs Per Capita) during the Study Period

| Year | Factor VIII | Factor VIII (plasma-derived) | Factor VIII (recombinant) | Factor IX | Factor IX (plasma-derived) | Factor IX (recombinant) |
|------|-------------|-------------------------------|---------------------------|-----------|----------------------------|-------------------------|
| 1997 | 0.9583      | 0.9583                        | 0.2306                    | 2.0147    | 0.0041                     | 0.0632                  |
| 1998 | 1.1023      | 0.9212                        | 0.2344                    | 2.0147    | 0.1363                     | 0.1363                  |
| 1999 | 1.2538      | 0.4592                        | 0.1437                    | 0.1218    | 0.1863                     | 0.1863                  |
| 2000 | 1.228       | 0.4592                        | 0.2741                    | 0.2892    | 0.329                      | 0.329                   |
| 2001 | 1.4083      | 0.3677                        | 0.3373                    | 0.3567    | 0.3778                     | 0.3778                  |
| 2002 | 1.5675      | 0.2702                        | 0.329                     | 0.3567    | 0.3778                     | 0.3778                  |
| 2003 | 1.6058      | 0.1927                        | 0.1705                    | 0.1705    | 0.1602                     | 0.1602                  |
| 2004 | 1.8044      | 0.285                         | 0.1927                    | 0.1927    | 0.1602                     | 0.1602                  |
| 2005 | 2.0147      | 0.2705                        | 0.1316                    | 0.1316    | 0.2028                     | 0.2028                  |
| 2006 | 2.2793      | 0.1725                        | 0.1139                    | 0.1139    | 0.0525                     | 0.0525                  |
| 2007 | 0.0041      | 0.0632                        | 0.1363                    | 0.1363    | 0.1863                     | 0.1863                  |

Table 5. Factor VIII and Factor IX Usage Per Patient (IUs Per PWHA or PWHB) during the Study Period

| Patients with hemophilia | PWHA | PWHB |
|--------------------------|------|------|
| Severe                   | 28622| 70603|
| Moderate                 | 47992| 5913 |
| Mild                     | 1116 | 5194 |
| PWHA                     | 38573| 58913|
| PWHB                     | 38934| 59146|

IUs, international units; SDs, standard deviation.
*Slope of the regression line.
†Correlation coefficient.
database was 6.7±0.1 (per 100000 males). Similar results were obtained in Japan (5.9±0.5), Korea (5.3±0.4),\textsuperscript{16} and Hong Kong (6.4),\textsuperscript{17} all of which were slightly lower than that reported in Singapore (7.8±0.2).\textsuperscript{16} Our results demonstrated a lower prevalence that those reported in the Netherlands (11.7),\textsuperscript{18} Italy (10.0),\textsuperscript{19} United Kingdom (21.4),\textsuperscript{20} Canada (14.3),\textsuperscript{21} and the United States (10.5).\textsuperscript{22} The mean prevalence of HB (all severities) was 1.2±0.1 (per 100000 males). Similar results were also obtained in Japan (1.3±0.1),\textsuperscript{21} Korea (5.3±0.4),\textsuperscript{23} and Singapore (1.1±0.1),\textsuperscript{21} which were slightly higher than the results reported for Korea (1.0±0.2),\textsuperscript{21} all of which were lower than the results for Italy (2.0),\textsuperscript{21} the United Kingdom (4.5),\textsuperscript{20} and Canada (3.3).\textsuperscript{24}

Recently, Stonebraker et al.\textsuperscript{16} reported on the prevalence of hemophilia for 106 countries between 1998 and 2006. The prevalence of HA (per 100000 males), according to the World Bank classification of high income (USD 11116) or more, for the Organization for Economic Co-operation and Development (OECD) and non-OECD countries was 12.8±6.0 and 8.4±4.0, respectively. Second, the prevalence of HA was 12.9±1.5 for Canada, 9.8±2.2 for the Netherlands, and 16.8±2.9 for the United Kingdom. Third, the prevalences of HA for Asian OECD and non-OECD counties, such as Japan, Korea, and Singapore, were lower than the average prevalence, which was also obviously lower than that frequently reported in the literature pertaining to Caucasians.

Few studies\textsuperscript{25,26} have reported on race/ethnicity differences in hemophilia epidemiology. The incidence of hemophilia among Chinese has been reported to be slightly lower than that in Caucasians.\textsuperscript{25} Soucie et al.\textsuperscript{22} reported the age-adjusted prevalence of hemophiliacs to be 13.2 (per 100000 males) among white Americans, 11.0 among African-Americans, 11.5 among Hispanic males, and 4.3 among Asian/Pacific Islanders in the United States. However, the results from Soucie et al.\textsuperscript{22} should be interpreted with caution based on the small number of cases and the variation in rates (0-15.3 per 100000 males) of Asian/Pacific Islanders in different states. Additionally, Chen et al.\textsuperscript{26} reported that the prevalence of an intron 22 inversion in Chinese patients with severe HA was less than that reported in previous studies in Caucasian populations based on a genetic analysis. The foregoing literature has revealed interesting differences in hemophilia due to race/ethnicity, demonstrating a need for further concern for such variations.

Compared to the general male population in Taiwan, the SMR for all individuals with hemophilia and those with severe hemophilia was 1.3- and 2-fold higher than that in the general male population. Similar results were obtained in previous studies\textsuperscript{5,27} that reported on the mortality rate and causes of death in hemophiliacs after a period that posed the greatest risk of blood-borne virus transmission. Plug et al.\textsuperscript{5} reported that among all individuals with hemophilia in the Netherlands between 1992 and 2001, the SMRs for human immunodeficiency virus (HIV)-positive and -negative individuals were 2.3 and 1.7 fold higher than that for the general male population, respectively, and these rates increased for those with severe hemophilia 5.1 and 2.8-fold, respectively. In a study of hemophilia in Italy, Tagliaferri et al.\textsuperscript{27} reported that the SMR among all hemophiliacs decreased from 2.0 over the years of 1990 to 1999 to an SMR of 1.1 over the years of 2000 to 2007, compared to the general male population. A similar shift in SMR was seen among individuals with severe hemophilia, decreasing from 4.1 (1990 to 1999) to 3.3 (2000 to 2007).

Acquired immunodeficiency syndrome (AIDS), resulting from HIV, and liver failure, caused by hepatitis C virus (HCV), contaminated concentrates produced before 1985. The most important cause of death during the 1970s and early 1980s was indeed replaced by AIDS as the leading cause of death during the late 1980s and early 1990s in hemophiliacs.\textsuperscript{28} During the last 10 years, the effect of HCV-related end-stage liver disease on mortality has become dominant.\textsuperscript{5} Unfortunately, in this study, NHIRD did not provide access to databases on mortality data, which would have been required to study causes of death, severity, and age differences, and to conduct other outcome assessments. According to the data retrievable from Taiwan’s Centers for Disease Control, 53 HIV-positive hemophilia cases have been reported to date. All of these HIV-positive individuals were diagnosed between 1984 and 1997, and 45 cases were diagnosed before 1990.\textsuperscript{29} This may be related to the use of contaminated blood concentrates in hemophiliacs before 1985 in Taiwan. The available data showed that 31 and five affected hemophiliacs died between 1984 and 2002 and 2003-2007.\textsuperscript{31} It is difficult to elucidate how many HIV-positive hemophiliacs contributed to our mortality rate results. Thus, further studies should address specific causes of death and other relevant issues.

**Factor usage**

Another objective of this study was to assess FVIII and FIX usage trends in Taiwan. The results of this study indicated an increasing trend in FVIII and FIX concentrate use in Taiwan.
Results for FVIII usage (1.5003±0.4029 IUs per capita) and FVIII usage per patient (44027±11532 IUs per PWHA), as an annual increase therein, were consistent with a previous report that FVIII usage (IUs per capita and IUs per PWHA) increased over time in most countries. Additionally, FVIII usage (IUs per capita) and FVIII usage per patient (IUs per PWHA) were similar to the mean results reported for high income non-OECD countries (1.4000±1.2381 and 47105±60130). Compared to Asian OECD and non-OECD counties, the results for mean FVIII usage (IUs per capita) was similar to those reported for Korea (1.2864±0.4170) and Hong Kong (1.4658±0.7319), slightly lower than that for Japan (1.9511±0.2272), and considerably higher than that for Singapore (0.6128±0.2129). The mean FVIII usage per patient (IUs per PWHA) results were similar to those reported in Korea (47048±14899), slightly lower than those reported in Japan (66797±6421), and considerably higher than those reported in Singapore (14940±6322).

In general, the goals of factor replacement therapy are to prevent joint and non-joint bleeding, and, thereby, retard the onset and/or delay the progression of disease. Factor consumption and drug utilization patterns are influenced by multiple variables, such as replacement therapy patterns, dose regimen protocol, reimbursement policy, and healthcare service type. Briefly, prophylaxis is recommended as the optimal therapy for patients with hemophilia by the World Federation of Hemophilia and the WHO. Prophylactic therapies have been widely adopted across Europe, North America, and Japan, but has only recently been initiated in Taiwan. In this context, treatment strategies and healthcare policies vary widely between countries, which greatly impact factor usage trends and direct cross-national comparisons.

In Taiwan, prior to the implementation of the NHI program, hemophiliacs only obtained a few factor concentrates for the relief of disease progression (arthropathies, disability, and other complications). After its implementation in 1995, the NHI program guaranteed that hemophiliacs would obtain better treatment. Numerous studies have shown that factor concentrates are the single greatest source of costs for hemophilia care. reported that factor concentrates accounted for >96.5% of the expenditures in Taiwan. Increasing the availability and use of factor concentrates has improved the quality of care for people with hemophilia in Taiwan. Unfortunately, treatment guidelines for patients with hemophilia have not been established. Moreover, further analysis showed that number of hospitals providing hemophilia care services increased from 32 hospitals in 2003 to 44 hospitals in 2007. Contrary to our expectation, the earliest hemophilia treatment center (HTC) was established in 1984 in Taiwan, and the number of HTCs and hospitals providing comprehensive care services for hemophiliacs remains small.

In addition, the mandatory NHI registry lacks data for essential clinical information, including viral infection status (HIV and HCV), immunization, treatment strategy, dose regimen, significant complications (inhibitors, liver disease, and joint disease), cause of death, and maternal carrier status. An accurate, simple, and complete registry system that ensures the quality of patient information for continued improvement of hemophilia treatment is needed.

To improve the registry, we suggest the establishment of a revised registry committee, with representatives from all key groups-patients, healthcare providers, and government representatives-who can offer different perspectives on how to achieve accuracy, simplicity, and completeness in the mandatory registry database. A user-friendly internet-based patient registry should be created to simplify data collection in the future. This could be modeled on existing successful internet-based registries, such as those for cancer or organ transplantation by the Department of Health (DOH) in Taiwan. The registry could be operated by the DOH, who could also organize an advisory board to standardize terminology, coding, and the internet platform. In addition, there should be an effort to increase the participation of hospitals, physicians, and specialized nurses who provide care and services for persons with hemophilia in providing data on newly diagnosed individuals to the registry. The Bureau of Health Promotion has promoted nationwide newborn screening services since 1985, and from 1997 to the end of 2007, the screening rates were reported to be higher than 99.5%. Newborns diagnosed with hemophilia should be referred for treatment and genetic counseling to prevent serious sequelae.

A national registry can be a dynamic tool for hemophilia care, and must be continually updated in order to remain accurate and useful. There should be policies in place to ensure that new data find their way into the registry after the set-up work is completed. The registry is also critical in the planning and evaluation of healthcare programs. Data should appear each year in a special bulletin and in an annual registry report published by the Ministry of Health. Analyses and observed trends need to be published in annual reports or in medical journals. The registry also provides a database regarding various future hemophilia research efforts.

Our study demonstrated ratios of 12.5 : 1 and 2.4 : 1 for...
A better designed and patient-centered registry system could empower more detailed information collection and subsequent analysis.

ACKNOWLEDGEMENTS

This study was sponsored by the Hemophilia Care and Research Center at the Tri-Service General Hospital in Taipei, Taiwan, and was also supported by a Baxter Education Fund.

REFERENCES

1. Fischer K, Van Den Berg M. Prophylaxis for severe haemophilia: clinical and economical issues. Haemophilia 2003;9:376-81.
2. Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001;344:1773-9.
3. Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007;110:815-25.
4. Franchini M, Tagliaferri A, Mannucci PM. The management of hemophilia in elderly patients. Clin Interv Aging 2007;2:361-8.
5. Plug I, Van Der Bom JG, Peters M, Mauser-Bunschoten EP, de Goede-Bolder A, Heijnen L, et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006;4:510-6.
6. Street A, Hill K, Sussex B, Warner M, Scully MF. Haemophilia and ageing. Haemophilia 2006;12 Suppl 3:8-12.
7. Plug I, Peters M, Mauser-Bunschoten EP, de Goede-Bolder A, Heijnen L, et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006;4:510-6.
8. Guidelines for the management of hemophilia. 2005. [accessed on 2012 Aug 8]. Available at: http://wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Guidelines_Mng_Hemophilia.pdf.
9. Cherishing health insurance for a healthy Taiwan 2006. [accessed on 2012 Aug 8]. Available at: http://www.nhi.gov.tw/Resource/webdata/Attach_13792_2_cherishing.pdf.
10. National Health Insurance in Taiwan 2011 Annual Report. [accessed on 2012 Aug 8]. Available at: http://www.nhi.gov.tw/Resource/webdata/13767_1_NHI%20IN%20TAIWAN%20
Tsu-Chiang Tu, et al.

2011%20ANNUAL%20REPORT.pdf.

11. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age Standardization of rates: a new WHO standard. 2001. [accessed on 2010 Aug 8]. Available at: http://www.who.int/healthinfo/paper31.pdf.

12. Population by age. [accessed on 2010 Aug 8]. Available at: http://sowf.moi.gov.tw/stat/year/y02-01.xls.

13. Causes of death statistics. [accessed on 2010 Aug 8]. Available at: http://www.doh.gov.tw/CHT2006/DisplayStatisticFile.aspx?id=73104&x=1.

14. Stonebraker JS, Brooker M, Amand RE, Farrugia A, Srivastava A. A study of reported factor VIII use around the world. Haemophilia 2010;16:33-46.

15. StataCorp LP, 4905 Lakeway Drive College Station, Texas 77845-4512, USA.

16. Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010;16:20-32.

17. Ling SC, Chan GCF, Shing MMK, Yuen HL, Lee ACW, Chan CW, et al. Children and Adolescents with Haemophilia in Hong Kong: an Epidemiological and Clinical Review. HK J Paediatri 2006;11:13-9.

18. Plug I, van der Bom JG, Peters M, Mauser-Bunschoten EP, de Goeede-Bolder A, Heijnen L, et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004;104:3494-500.

19. Iorio A, Olivociello E, Morfini M, Mannucci PM; Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia 2008;14:444-53.

20. Annual Report 2009. United Kingdom Haemophilia Centre Doctors’ Organisation 2009. [accessed on 2010 Aug 8]. Available at: http://www.ukhcdn.org/docs/AnnualReports/2009/Annual%20Report%202009%20slides.pdf.

21. Canadian Hemophilia registry-Factor VIII. Hemophilia A 2009. [accessed on 2010 Aug 8]. Available at: http://ths.mcmaster.ca/chr/pdf/09/CHRVIIF090413.pdf.

22. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998;59:288-94.

23. Stonebraker JS, Bolton-Maggs PHB, Soucie JM, Walker I, Brooker M. A study of variations in the reported hemophilia B prevalence around the world. [accessed on 2011 Dec 10]. Available at: http://www1.wfh.org/2/docs/Publications/Statistics/DDP-10_Prevalence_HemophiliaB.pdf.

24. Canadian Hemophilia registry-Factor IX. Hemophilia B 2009. [accessed on 8 Aug 2010]. Available at: http://ths.mcmaster.ca/chr/pdf/09/CHR IXIF090413.pdf.

25. Chan V, Chan TK, Liu VW, Wong AC. Restriction fragment length polymorphisms associated with factor VIII: C gene in Chinese. Hum Genet 1988;79:128-31.

26. Chen YC, Hu SH, Cheng SN, Chao TY. Genetic analysis of haemophilia A in Taiwan. Haemophilia 2010;16:538-44.

27. Tagliaferri A, Rivolta GF, Iorio A, Olivociello E, Mancuso ME, Morfini M, et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010;16:437-46.

28. Mejia-Carvajal C, Czapek EE, Valeriano LA. Life expectancy in hemophilia outcome. J Thromb Haemost 2006;4:507-9.

29. Cases of HIV/AIDS by exposure category. [accessed on 2012 Aug 8]. Available at: http://www.cdc.gov.tw/downloadfile.aspx?fid=BFFEE6AB018CFAF8.

30. Statistics of HIV/AIDS 1984-2003/1/31. [accessed on 2010 Aug 8]. Available at: http://www2.cdc.gov.tw/public/Data/8121710212971.pdf.

31. Statistics of HIV/AIDS 1984-2007/12/31. [accessed on 2010 Aug 8]. Available at: http://www.cdc.gov.tw/english/info.aspx?treeid=00ed756c88787b27&nowtreeid=1d256e6c8b243c1d&tid=11E0691878D687950.

32. Bernstorp E, Bouljyjenkov V, Brettler D, Chandy M, Jones P, Lee C, et al. Modern treatment of haemophilia. Bull World Health Organ 1995;73:691-701.

33. Ono O, Suzuki Y, Yosikawa K, Wada I, Doi Y, Takano M, et al. Assessment of haemophilia treatment practice pattern in Japan. Haemophilia 2009;15:1032-8.

34. Carcao MD, Aledort LM; Round Table Group. Prophylaxis in the haemophilia population-optimizing therapy. Haemophilia 2007;13:227-32.

35. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 1996;129:424-31.

36. Carlsson KS, Höögård S, Lindgren A, Lethagen S, Schulman S, Glomstein A, et al. Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia 2004;10:515-26.

37. Heemstra HE, Zwaan T, Hemels M, Feldman BM, Blanchette V, Kern M, et al. Cost of severe haemophilia in Toronto. Haemophilia 2005;11:254-60.

38. Liou WS, Tu TC; Cheng SN, Chou TY, Lee CF, Lin TK, et al. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan. Haemophilia 2011;17:45-54.

39. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost 2009;101:674-81.

40. Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006;12 Suppl 6:102-6.

41. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9:418-35.

42. Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. Blood 2006;107:46-51.

43. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe haemophilia A: the CANAL cohort study. Blood 2007:109:4693-7.

44. Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007;13:149-55.

45. Coppola A, Santoro C, Tagliaferri A, Franchini M, DI Minno G, Mannucci PM. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia 2010;16 Suppl 1:13-9.

46. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in hemophilia A therapy -- global progress towards optimal care. Haemophilia 2006;12:75-81.